8-K: Larimar Therapeutics Targets Accelerated Approval for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics is advancing its nomlabofusp program for Friedreich's ataxia, targeting a BLA submission by year-end 2025 and potential accelerated approval based on skin FXN concentrations.

Summary

• Larimar Therapeutics is focused on developing nomlabofusp (CTI-1601) as a potential disease-modifying therapy for Friedreich's ataxia (FA).
• Nomlabofusp is designed to address frataxin deficiency by delivering a recombinant fusion protein to mitochondria.
• The company is targeting a Biologics License Application (BLA) submission by year-end 2025, seeking accelerated approval.
• The FDA is open to considering skin FXN concentration as a reasonably likely surrogate endpoint (RLSE) for accelerated approval.
• Clinical trials have shown that nomlabofusp increases and maintains tissue FXN concentrations over time.
• Topline data from the 50 mg Open Label Extension (OLE) study and data from the adolescent cohort of the PK run-in study are expected in September 2025.
• Larimar plans to initiate a global Phase 3 study in mid-2025.
• As of March 31, 2025, Larimar had $157.5 million in cash and investments, with a projected cash runway into Q2 2026.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the potential for accelerated approval and ongoing clinical trials showing promising results. However, the mention of adverse events and the need for premedication temper the overall sentiment.

Positives

• The FDA is open to considering skin FXN concentration as a reasonably likely surrogate endpoint for accelerated approval, potentially speeding up the approval process.
• Nomlabofusp has shown dose-dependent increases in frataxin levels in tissues tested (skin and buccal cells).
• The company has a strong IP portfolio with a granted composition of matter patent extending into 2040.
• Larimar has been selected to participate in the FDA START pilot program, which aims to accelerate the development of novel therapies for rare diseases.
• The company has a good relationship with FARA (Friedreich's Ataxia Research Alliance) for patient recruitment and education.

Negatives

• Anaphylaxis was determined to be an adverse drug reaction likely associated with nomlabofusp, requiring patients to be premedicated for the first month of dosing.
• Two participants in the OLE study had serious adverse events that resolved within 24 hours and withdrew from the study.

Risks

• The acceptability of FXN concentrations as a reasonably likely surrogate endpoint to support approval will be a matter of review in a future marketing application.
• The success of Larimar's product development activities, nonclinical studies, and clinical trials are subject to risks and uncertainties.
• Delays in patient recruitment could impact the timelines for clinical trials.
• The company's ability to raise the necessary capital to conduct its product development activities is a risk factor.
• The potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions is a risk.

Future Outlook

Larimar is focused on advancing nomlabofusp through clinical trials, seeking accelerated approval based on skin FXN concentrations, and planning for a global Phase 3 study. The company anticipates a BLA submission by year-end 2025.

Management Comments

• FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint (RLSE) in support of an accelerated approval.
• The acceptability of FXN concentrations as an RLSE to support approval will be a matter of review in a future marketing application.

Industry Context

Larimar is positioned to potentially be the first disease-modifying therapy for Friedreich's ataxia, a rare and progressive disease with limited treatment options. The competitive landscape includes companies like Biogen and PTC Therapeutics, but Larimar's protein replacement approach differentiates it from other mechanisms of action.

Comparison to Industry Standards

• Biogen's Omaveloxolone (SKYCLARYS) is an approved therapy for FA, but it acts as a mitochondrial oxidative stress modifier rather than directly addressing frataxin deficiency like Larimar's Nomlabofusp.
• PTC Therapeutics' Vatiquinone is another competitor in Phase III trials, working as a 15-Lipoxygenase Inhibitor.
• Lexeo Therapeutics is developing LX2006, a gene therapy for Frataxin Gene Replacement in Phase I/II trials.

Stakeholder Impact

• Positive impact on patients with Friedreich's ataxia if nomlabofusp is approved, providing a potential disease-modifying therapy.
• Potential positive impact on shareholders if the company achieves its clinical and regulatory milestones.
• Potential impact on employees as the company progresses through clinical trials and regulatory submissions.

Next Steps

• Continue enrolling patients in the ongoing 50 mg dose Open Label Extension (OLE) study.
• Introduce the lyophilized dosage form into clinical studies in mid-2025.
• Initiate the global Phase 3 study in mid-2025.
• Seek feedback from the FDA to determine the adequacy of the safety data set to support the BLA submission.
• Submit the Biologics License Application (BLA) seeking accelerated approval by year-end 2025.

Key Dates

Keywords

nomlabofusp, Friedreich's ataxia, frataxin, FDA, accelerated approval, clinical trials, CTI-1601, rare disease, BLA, START pilot program